Department of Life Sciences, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania.
The Regenerative Clinic, London, United Kingdom.
Front Immunol. 2022 Mar 4;13:866379. doi: 10.3389/fimmu.2022.866379. eCollection 2022.
Monomeric C-reactive protein (mCRP), once thought to be a figment of the imagination and whose biological activity was ascribed to its sodium azide preservative, has now pronounced itself as a critical molecule playing a direct role in mediating many of the acute and chronic aberrant pathological responses to inflammation. In this focused mini review, we describe the currently attributed pathobiological interactions of mCRP in disease, where its tissue and cellular distribution and deposition have recently been clearly characterized and linked to inflammation and other pathway-associated progression of neurological and cardiovascular complications and deleterious outcomes. and focus upon current opinions as to the diagnostic and prognostic potential of mCRP-plasma circulating protein and define the possible future therapeutics including ongoing research attempting to block CRP dissociation with small molecule inhibitors or prevention of cell surface binding directly using antibodies or modified orphan drug targeting directed towards CRP, inhibiting its cellular interactions and signaling activation. There is no doubt that understanding the full influence of the biological power of mCRP in disease development and outcome will be considered a critical parameter in future stratified treatment.
单体 C 反应蛋白（mCRP），曾被认为是想象的产物，其生物活性归因于其叠氮化钠防腐剂，现在已经明确表明自己是一种关键分子，在介导许多急性和慢性炎症异常病理反应中发挥直接作用。在这篇重点迷你综述中，我们描述了 mCRP 在疾病中的当前归因的病理生物学相互作用，其中其组织和细胞分布和沉积最近已被明确表征，并与炎症和其他与途径相关的神经和心血管并发症及有害后果的进展相关联。我们关注 mCRP-血浆循环蛋白的当前观点，作为诊断和预后的潜力，并定义可能的未来治疗方法，包括正在进行的研究，试图使用小分子抑制剂阻断 CRP 解离，或直接使用抗体或修饰的孤儿药物靶向细胞表面结合，抑制其细胞相互作用和信号激活。毫无疑问，了解 mCRP 在疾病发展和结局中的生物学作用的全部影响，将被认为是未来分层治疗的一个关键参数。
